Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Symposium on Target Organ Toxicity: cardiovascular system. The epidemiologic approach.

Environmental health perspectives

Pell S.
PMID: 720318
Environ Health Perspect. 1978 Oct;26:269-73. doi: 10.1289/ehp.7826269.
Free PMC Article

Epidemiological studies rarely provide unequivocal data on the effects of toxic substances on human health. Unlike experimental studies, pertinent variables frequently cannot be controlled and some are often unknown. Nevertheless, these limitations can be dealt with by various facets...

Cite
Pell S. Symposium on Target Organ Toxicity: cardiovascular system. The epidemiologic approach. Environ Health Perspect. 1978;26:269-73doi: 10.1289/ehp.7826269.
Pell, S. (1978). Symposium on Target Organ Toxicity: cardiovascular system. The epidemiologic approach. Environmental health perspectives, 26269-73. https://doi.org/10.1289/ehp.7826269
Pell, S. "Symposium on Target Organ Toxicity: cardiovascular system. The epidemiologic approach." Environmental health perspectives vol. 26 (1978): 269-73. doi: https://doi.org/10.1289/ehp.7826269
Pell S. Symposium on Target Organ Toxicity: cardiovascular system. The epidemiologic approach. Environ Health Perspect. 1978 Oct;26:269-73. doi: 10.1289/ehp.7826269. PMID: 720318; PMCID: PMC1637238.
Copy Download .nbib Format: NLM
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

Critical reviews in oncology/hematology

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC.
PMID: 21330149
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16.

Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities,...

Cite
Ederhy S, Izzedine H, Massard C, et al. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369-79doi: 10.1016/j.critrevonc.2011.01.009.
Ederhy, S., Izzedine, H., Massard, C., Dufaitre, G., Spano, J. P., Milano, G., Meuleman, C., Besse, B., Boccara, F., Kahyat, D., Cohen, A., & Soria, J. C. (2011). Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Critical reviews in oncology/hematology, 80(3), 369-79. https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy, Stephane, et al. "Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists." Critical reviews in oncology/hematology vol. 80,3 (2011): 369-79. doi: https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16. PMID: 21330149.
Copy Download .nbib Format: NLM
[Research progress on the immune checkpoint inhibitors induced cardiotoxicity].

Zhonghua xin xue guan bing za zhi

Lyu SS, Yang YM.
PMID: 31550849
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Sep 24;47(9):748-751. doi: 10.3760/cma.j.issn.0253-3758.2019.09.019.

No abstract available.

Cite
Lyu SS, Yang YM. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(9):748-751doi: 10.3760/cma.j.issn.0253-3758.2019.09.019.
Lyu, S. S., & Yang, Y. M. (2019). [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua xin xue guan bing za zhi, 47(9), 748-751. https://doi.org/10.3760/cma.j.issn.0253-3758.2019.09.019
Lyu, S S, and Yang, Y M. "[Research progress on the immune checkpoint inhibitors induced cardiotoxicity]." Zhonghua xin xue guan bing za zhi vol. 47,9 (2019): 748-751. doi: https://doi.org/10.3760/cma.j.issn.0253-3758.2019.09.019
Lyu SS, Yang YM. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Sep 24;47(9):748-751. doi: 10.3760/cma.j.issn.0253-3758.2019.09.019. Chinese. PMID: 31550849.
Copy Download .nbib Format: NLM
Heart failure induced by non-cardiac drugs.

Drug safety

Slørdal L, Spigset O.
PMID: 16808550
Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003.

Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely...

Cite
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86doi: 10.2165/00002018-200629070-00003.
Slørdal, L., & Spigset, O. (2006). Heart failure induced by non-cardiac drugs. Drug safety, 29(7), 567-86. https://doi.org/10.2165/00002018-200629070-00003
Slørdal, Lars, and Spigset, Olav. "Heart failure induced by non-cardiac drugs." Drug safety vol. 29,7 (2006): 567-86. doi: https://doi.org/10.2165/00002018-200629070-00003
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003. PMID: 16808550.
Copy Download .nbib Format: NLM
[Cardiologic evaluation of patients undergoing chemotherapy].

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

Bordoni B, Urbinati S, Tosoni A, Labanti G, Brandes A.
PMID: 25845089
Monaldi Arch Chest Dis. 2014 Jun;82(2):68-74. doi: 10.4081/monaldi.2014.46.

Life expectancy in patients affected by cancer has recently increased because of early diagnosis and actual therapies. In recent years, Oncology and Cardiology developed a tight relationship because of common risk factors (i.e., obesity, smoking, alcool intake, etc...), and...

Cite
Bordoni B, Urbinati S, Tosoni A, et al. La consulenza cardiologica "mirata" nel paziente oncologico sottoposto a chemioterapia: come prevenire e monitorare la cardiotossicità in maniera appropriate. [Cardiologic evaluation of patients undergoing chemotherapy]. Monaldi Arch Chest Dis. 2014;82(2):68-74doi: 10.4081/monaldi.2014.46.
Bordoni, B., Urbinati, S., Tosoni, A., Labanti, G., & Brandes, A. (2014). La consulenza cardiologica "mirata" nel paziente oncologico sottoposto a chemioterapia: come prevenire e monitorare la cardiotossicità in maniera appropriate. [Cardiologic evaluation of patients undergoing chemotherapy]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 82(2), 68-74. https://doi.org/10.4081/monaldi.2014.46
Bordoni, Barbara, et al. "La consulenza cardiologica "mirata" nel paziente oncologico sottoposto a chemioterapia: come prevenire e monitorare la cardiotossicità in maniera appropriate." [Cardiologic evaluation of patients undergoing chemotherapy]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace vol. 82,2 (2014): 68-74. doi: https://doi.org/10.4081/monaldi.2014.46
Bordoni B, Urbinati S, Tosoni A, Labanti G, Brandes A. La consulenza cardiologica "mirata" nel paziente oncologico sottoposto a chemioterapia: come prevenire e monitorare la cardiotossicità in maniera appropriate. [Cardiologic evaluation of patients undergoing chemotherapy]. Monaldi Arch Chest Dis. 2014 Jun;82(2):68-74. doi: 10.4081/monaldi.2014.46. Italian. PMID: 25845089.
Copy Download .nbib Format: NLM
Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.

Medicine

Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y.
PMID: 27858859
Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195.

BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is...

Cite
Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016;95(44):e5195doi: 10.1097/MD.0000000000005195.
Jawa, Z., Perez, R. M., Garlie, L., Singh, M., Qamar, R., Khandheria, B. K., Jahangir, A., & Shi, Y. (2016). Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine, 95(44), e5195. https://doi.org/10.1097/MD.0000000000005195
Jawa, Zeeshan, et al. "Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis." Medicine vol. 95,44 (2016): e5195. doi: https://doi.org/10.1097/MD.0000000000005195
Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195. PMID: 27858859; PMCID: PMC5591107.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries